Newsletter | June 23, 2026

06.23.26 -- STREAM Edition: Why In Vivo Therapies Are Moving Toward The Clinic With Ascidian Therapeutics' Dr. Mike Ehlers

SPONSOR

 

Webinar: A Closer Look at How Single Use Consumables Drive Cost per Therapy

Single-use consumables play a critical role in cell and gene therapy manufacturing, influencing cost per therapy, scalability, and operational risk. Join Invetech to explore how early consumable design decisions impact development through commercialization, where consumables add value, and how to identify cost and risk signals sooner. Learn strategies to support efficient scale-up, validation, and long-term manufacturing success. Click here to learn more.

Capabilities In Cell & Gene Therapy Manufacturing

Video | Lonza

A global CDMO outlines end-to-end capabilities in cell and gene therapy, mRNA, and microbial platforms, emphasizing scalability, innovation, and seamless development through commercial manufacturing.

Scaling Plasmid DNA Production: A Proven Strategy For Higher Yields

Webinar | Thermo Fisher Scientific Bioproduction

Learn how an agile manufacturing partner scaled their plasmid DNA production and achieved higher yields by optimizing their media selection and fermentation processes.

 

Automating Ancillary Processes: Closing Bottlenecks In CGT Manufacturing

Webinar | Invetech

Watch as speakers share a variety of challenges encountered when closing and automating ancillary processes, and how closed automated platforms improved scalability and reproducibility.

Mobilizing Science, Partnership, And Capability To Develop A Therapy In 14 Months

Webinar | Andelyn Biosciences

Hear how one family, driven by urgency, partnered with AAV experts to develop a treatment for their daughter’s ultra-rare neurodegenerative disorder, NEDAMSS, in just 14 months.

Why In Vivo Therapies Are Moving Toward The Clinic With Ascidian Therapeutics' Dr. Mike Ehlers

Video | Cell & Gene

This is episode 3 of our in vivo-focused special series of Cell & Gene: The Podcast. Here, Ascidian Therapeutics' Founder, President, and CEO Mike Ehlers, M.D., Ph.D., explains how the company is advancing a new class of genetic medicines built on RNA exon editing to durably correct disease at the transcript level without permanently altering DNA.

Detecting Particles In Biologic And CGT Drug Products

Webinar | Coriolis Pharma

Identify and characterize visible and subvisible particles that can form during biologic and cell or gene therapy development.

Connect With Cell & Gene: